NASDAQ:CRNX

Crinetics Pharmaceuticals Competitors

$17.07
-0.83 (-4.64 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.92
Now: $17.07
$18.96
50-Day Range
$14.45
MA: $15.98
$17.90
52-Week Range
$11.61
Now: $17.07
$23.70
Volume268,873 shs
Average Volume137,520 shs
Market Capitalization$563.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.24

Competitors

Crinetics Pharmaceuticals (NASDAQ:CRNX) Vs. RCUS, PBH, IGMS, RVNC, DRNA, and AXSM

Should you be buying CRNX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Crinetics Pharmaceuticals, including Arcus Biosciences (RCUS), Prestige Consumer Healthcare (PBH), IGM Biosciences (IGMS), Revance Therapeutics (RVNC), Dicerna Pharmaceuticals (DRNA), and Axsome Therapeutics (AXSM).

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 60.6% of Arcus Biosciences shares are held by institutional investors. 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 19.7% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Crinetics Pharmaceuticals and Arcus Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$1.19 million473.79$-50,420,000.00($2.09)-8.17
Arcus Biosciences$15 million147.89$-84,710,000.00($1.93)-16.22

Crinetics Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Crinetics Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Profitability

This table compares Crinetics Pharmaceuticals and Arcus Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crinetics PharmaceuticalsN/A-43.35%-39.73%
Arcus Biosciences-112.63%-27.43%-20.96%

Analyst Ratings

This is a summary of recent ratings for Crinetics Pharmaceuticals and Arcus Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crinetics Pharmaceuticals01302.75
Arcus Biosciences00903.00

Crinetics Pharmaceuticals presently has a consensus price target of $35.00, indicating a potential upside of 105.04%. Arcus Biosciences has a consensus price target of $49.9091, indicating a potential upside of 59.45%. Given Crinetics Pharmaceuticals' higher possible upside, equities analysts clearly believe Crinetics Pharmaceuticals is more favorable than Arcus Biosciences.

Summary

Arcus Biosciences beats Crinetics Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Crinetics Pharmaceuticals and Prestige Consumer Healthcare's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$1.19 million473.79$-50,420,000.00($2.09)-8.17
Prestige Consumer Healthcare$963.01 million2.27$142.28 million$2.9614.78

Prestige Consumer Healthcare has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Crinetics Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Crinetics Pharmaceuticals and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crinetics PharmaceuticalsN/A-43.35%-39.73%
Prestige Consumer Healthcare17.03%13.76%4.80%

Analyst Ratings

This is a summary of recent ratings for Crinetics Pharmaceuticals and Prestige Consumer Healthcare, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crinetics Pharmaceuticals01302.75
Prestige Consumer Healthcare04302.43

Crinetics Pharmaceuticals presently has a consensus price target of $35.00, indicating a potential upside of 105.04%. Prestige Consumer Healthcare has a consensus price target of $87.60, indicating a potential upside of 100.23%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Crinetics Pharmaceuticals is more favorable than Prestige Consumer Healthcare.

Summary

Prestige Consumer Healthcare beats Crinetics Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Crinetics Pharmaceuticals (NASDAQ:CRNX) and IGM Biosciences (NASDAQ:IGMS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 47.6% of IGM Biosciences shares are held by institutional investors. 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 79.3% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Crinetics Pharmaceuticals and IGM Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$1.19 million473.79$-50,420,000.00($2.09)-8.17
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.27

IGM Biosciences has lower revenue, but higher earnings than Crinetics Pharmaceuticals. IGM Biosciences is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Crinetics Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of -1.12, meaning that its share price is 212% less volatile than the S&P 500.

Profitability

This table compares Crinetics Pharmaceuticals and IGM Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crinetics PharmaceuticalsN/A-43.35%-39.73%
IGM BiosciencesN/A-33.30%-30.28%

Analyst Ratings

This is a summary of recent ratings for Crinetics Pharmaceuticals and IGM Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crinetics Pharmaceuticals01302.75
IGM Biosciences01602.86

Crinetics Pharmaceuticals presently has a consensus price target of $35.00, indicating a potential upside of 105.04%. IGM Biosciences has a consensus price target of $98.8750, indicating a potential upside of 44.36%. Given Crinetics Pharmaceuticals' higher possible upside, equities analysts clearly believe Crinetics Pharmaceuticals is more favorable than IGM Biosciences.

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Revance Therapeutics (NASDAQ:RVNC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent ratings for Crinetics Pharmaceuticals and Revance Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crinetics Pharmaceuticals01302.75
Revance Therapeutics00503.00

Crinetics Pharmaceuticals presently has a consensus price target of $35.00, indicating a potential upside of 105.04%. Revance Therapeutics has a consensus price target of $36.40, indicating a potential upside of 29.40%. Given Crinetics Pharmaceuticals' higher possible upside, equities analysts clearly believe Crinetics Pharmaceuticals is more favorable than Revance Therapeutics.

Insider and Institutional Ownership

92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are held by institutional investors. 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Revance Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Crinetics Pharmaceuticals and Revance Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crinetics Pharmaceuticals$1.19 million473.79$-50,420,000.00($2.09)-8.17
Revance Therapeutics$410,000.004,897.57$-159,430,000.00($3.67)-7.66

Crinetics Pharmaceuticals has higher revenue and earnings than Revance Therapeutics. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Crinetics Pharmaceuticals has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Profitability

This table compares Crinetics Pharmaceuticals and Revance Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crinetics PharmaceuticalsN/A-43.35%-39.73%
Revance Therapeutics-5,818.87%-85.72%-44.85%

Summary

Crinetics Pharmaceuticals beats Revance Therapeutics on 9 of the 14 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Dicerna Pharmaceuticals and Crinetics Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals00603.00
Crinetics Pharmaceuticals01302.75

Dicerna Pharmaceuticals presently has a consensus price target of $37.8333, indicating a potential upside of 45.01%. Crinetics Pharmaceuticals has a consensus price target of $35.00, indicating a potential upside of 105.04%. Given Crinetics Pharmaceuticals' higher possible upside, analysts clearly believe Crinetics Pharmaceuticals is more favorable than Dicerna Pharmaceuticals.

Insider & Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. Comparatively, 92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are held by company insiders. Comparatively, 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Dicerna Pharmaceuticals and Crinetics Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million83.31$-120,460,000.00($1.76)-14.82
Crinetics Pharmaceuticals$1.19 million473.79$-50,420,000.00($2.09)-8.17

Crinetics Pharmaceuticals has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Dicerna Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.

Profitability

This table compares Dicerna Pharmaceuticals and Crinetics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%
Crinetics PharmaceuticalsN/A-43.35%-39.73%

Axsome Therapeutics (NASDAQ:AXSM) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Axsome Therapeutics and Crinetics Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axsome Therapeutics101102.83
Crinetics Pharmaceuticals01302.75

Axsome Therapeutics presently has a consensus price target of $146.90, indicating a potential upside of 177.22%. Crinetics Pharmaceuticals has a consensus price target of $35.00, indicating a potential upside of 105.04%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Axsome Therapeutics is more favorable than Crinetics Pharmaceuticals.

Insider & Institutional Ownership

63.6% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 92.2% of Crinetics Pharmaceuticals shares are held by institutional investors. 26.0% of Axsome Therapeutics shares are held by company insiders. Comparatively, 7.1% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Axsome Therapeutics and Crinetics Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome TherapeuticsN/AN/A$-68,350,000.00($2.01)-26.36
Crinetics Pharmaceuticals$1.19 million473.79$-50,420,000.00($2.09)-8.17

Crinetics Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Axsome Therapeutics has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.

Profitability

This table compares Axsome Therapeutics and Crinetics Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axsome TherapeuticsN/A-62.33%-47.87%
Crinetics PharmaceuticalsN/A-43.35%-39.73%


Crinetics Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$31.30-1.3%$2.22 billion$15 million-16.39
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.75-0.5%$2.18 billion$963.01 million13.59Analyst Upgrade
News Coverage
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$68.49-16.4%$2.10 billionN/A-29.14Insider Selling
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.4%$2.01 billion$410,000.00-6.12
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$26.09-1.3%$1.99 billion$23.90 million-16.20Analyst Revision
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.99-2.1%$1.98 billionN/A-19.70
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Gap Down
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Gap Down
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88Gap Down
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00Gap Down
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.